• QVQ holding has joined the Biotech Investissement group and is now a sister company of RD-Biotech SAS, Diaclone SAS and SynAbs SA (www.mabexperts.com)

We are pleased to announce that QVQ holding has joined the Biotech Investissement group and is now a sister company of RD-Biotech SAS, Diaclone SAS and SynAbs SA (www.mabexperts.com).

RD-Biotech is a well experienced CRO which supplies high quality custom services in biomanufacturing (plasmids, monoclonal antibodies and recombinant antibodies, recombinant proteins, cells) and research contracts in molecular biology, immunology and cell engineering. In addition, RD-Biotech provides a range of FastELISA kits for the quantification of IgG from various species (mouse, rat, human, bovine)

With over 30 years of experience and expertise in immunology and more than 1.000 references, Diaclone is a firmly established centre of excellence in monoclonal antibody and Immunoassay kits (ELISA, ELISpots and DIAplex) for R&D and in vitro diagnostics. Moreover, Diaclone supplies custom services in development of murine monoclonal antibodies and, more recently, recombinant antibodies by phage display technology.

SynAbs, created in 2015 as a spin off from UCL (Université Catholique Louvain), offers a portfolio of services and products in Immunology, dedicated to R & D and in vitro diagnostics, with a catalog of more than 150 references of secondary antibodies. SynAbs has an extensive expertise in the development of monoclonal antibodies in rats (LOU rats), as well as in mice and guinea pig using highly innovative technologies.

By joining the Biotech Investissement group, QVQ will complete the high level of expertise and various service offer already known within the group, to develop and market new high-quality diagnostic assays and imaging products.

Please do not hesitate to get in touch if you require information about the products and services of the group.